SANTHERA N news, videos and press releases - Page 3
For more news please use our advanced search feature.
SANTHERA N - More news...
SANTHERA N - More news...
- Santhera Receives Financing Commitment of up to CHF 20 Million from Fund Managed by Highbridge Capital Management
- Santhera Announces Completion of ReveraGen’s Long-Term Extension Study with Vamorolone in Duchenne Muscular Dystrophy
- Santhera Provides Update on the Ongoing Regulatory Review of Puldysa® (Idebenone) by the CHMP in Duchenne Muscular Dystrophy (DMD)
- Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy (DMD)
- Santhera and Cold Spring Harbor Laboratory to Investigate Lonodelestat (POL6014) in COVID-19-related Acute Respiratory Distress Syndrome (ARDS)
- Santhera Enters into Equity-linked Financing to Provide up to CHF 12 million with the Option to Increase to up to CHF 24 million
- Santhera Appoints New Chief Financial Officer
- Santhera Appoints New Chief Executive Officer
- Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne Muscular Dystrophy
- Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses
- Santhera Announces Publication of Phase I Clinical Data with POL6014 in Journal of Cystic Fibrosis
- Santhera Announces Executive Management Change
- Santhera Announces Closing of Licensing Transaction with Chiesi Group for Raxone® in LHON
-
Santhera Pharms Holding
